Lipotec has launched Inyline, a novel antiageing hexapeptide for cosmetic applications to treat wrinkles caused by muscle contraction. Mimic facial muscle actions occur as frequently as blinking, smiling or frowning and it is through the modulation of the contraction mechanism that the most reliable and safe solution to escaping from expression lines can be sought.
One of the most evident ageing signs, expression lines are mainly located on the forehead, glabellar region, crow’s feet area or upper lip, and progressively become permanent. Lipotec first achieved muscle relaxation by inhibiting the release of the neurotransmitter acetylcholine (ACh) from a motor neuron, at a pre-synaptic stage across the neuromuscular junction. It is a strategy that offered new peptides to the anti-wrinkle market. Lipotec now brings to those independent mechanisms and possible peptide combinations an additional and innovative approach for treating expression wrinkles. Inyline acts once the ACh has been released from the motor neuron, before the signal is transmitted to the receptors (AChRs), at the post-synaptic stage. This new product targets the activation of MuSK (Muscle-Specific Kinase) by agrin, and thus disrupts AChRs from clustering, one of the requirements for the ACh to trigger the contraction signal along the neuromuscular junction. Inyline modulates the muscle contraction, acting as a competitive antagonist of MuSK at the agrin binding site, leading to the muscle relaxation required to attenuate expression wrinkles. As the in vivo efficacy results demonstrated after 28 days of treatment.
